REGENXBIO Inc.
RGNX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001590877
In the last 90 days, REGENXBIO Inc. insiders filed 1 open-market purchase and 0 sales; 166 institutions reported holding it in 13F filings for Q2 2026, worth $504.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 12, 2026
- $531.0M
- Insider buysLast 90 days, $949.4K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −10 vs. previous quarter
- 166
- 13F valueReported value at the end of Q2 2026
- $504.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $170.4M
- +104.5% year over year
- Net income, FY2025
- -$193.9M
- No comparable prior period
- Free cash flow, FY2025
- -$126.4M
- No comparable prior period
- Revenue, Q3 FY2026
- $9.16M
- −69.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $193.9M (113.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.2M
- Shares sold short
- Change
- +136.0K
- +1.4% vs. previous
- Days to cover
- 8.29
- At average daily volume
Superinvestors holding RGNX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding RGNX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by REGENXBIO Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 (view filing)7:03 PM ET | Aug 26-27 | 1 day | Ciongoli Gregory AustinDirector | PPurchase | +102.6K | $9.25 | +$949.4K | +664.9%118.0K after | 2 lots |
| Jul 6, 2026 (view filing)4:51 PM ET | Jul 2 | 4 days | Pakola SteveChief Medical Officer | SSale | −2.16K | $13.64 | −$29.5K | −1.0%213.0K after | 10b5-1 |
| Jul 1, 2026 (view filing)8:08 PM ET | Jun 29-Jul 1 | 2 days | Pakola SteveChief Medical Officer | SSale | −56.3K | $12.23 | −$688.8K | −20.9%213.0K after | 2 lots |
| May 13, 2026 (view filing) | May 11 | 2 days | Pakola SteveChief Medical Officer | SSale | −15.3K | $11.02 | −$168.7K | −6.2%232.6K after | 10b5-1 |
| Mar 12, 2026 (view filing) | Mar 10 | 2 days | Pakola SteveChief Medical Officer | SSale | −5.12K | $10.35 | −$53.0K | −2.0%247.9K after | 10b5-1 |
| Oct 10, 2025 (view filing) | Oct 9 | 1 day | Simpson CurranChief Executive Officer | SSale | −20.8K | $12.62 | −$262.6K | −8.8%216.2K after | 10b5-1 |
| Oct 1, 2025 (view filing) | Sep 29 | 2 days | Simpson CurranChief Executive Officer | SSale | −7.62K | $10.03 | −$76.5K | −3.1%237.0K after | 10b5-1 |
| Sep 12, 2025 (view filing) | Sep 10 | 2 days | Simpson CurranChief Executive Officer | SSale | −7.73K | $10.02 | −$77.5K | −3.1%244.6K after | 10b5-1 |
| May 14, 2025 (view filing) | May 12 | 2 days | Mills Kenneth T.Director | SSale | −20.6K | $7.91 | −$163.0K | −4.2%475.1K after | 10b5-1 |
| Oct 2, 2024 (view filing) | Oct 1 | 1 day | Karabelas Argeris NDirector | SSale | −10.0K | $10.11 | −$101.1K | −47.0%11.3K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 166 holdersThe largest institutional positions in REGENXBIO Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,397,440 | $76.6M | 0.00% | +614,632+10.6% | Added |
| Redmile Group, LLC | 4,368,804 | $52.3M | 3.51% | 00.0% | Unchanged |
| State Street Corp | 2,971,173 | $35.6M | 0.00% | +239,688+8.8% | Added |
| JPMorgan Chase & Co | 2,214,169 | $26.2M | 0.00% | −1,269,631−36.4% | Reduced |
| Vanguard Capital Management LLC | 2,107,557 | $25.2M | 0.00% | +100,411+5.0% | Added |
| Morgan Stanley | 1,953,237 | $23.4M | 0.00% | −112,920−5.5% | Reduced |
| Goldman Sachs Group Inc | 1,421,453 | $17.0M | 0.00% | −418,010−22.7% | Reduced |
| AQR Capital Management LLC | 1,378,358 | $16.5M | 0.01% | +326,646+31.1% | Added |
| Vanguard Portfolio Management LLC | 1,355,554 | $16.2M | 0.00% | +336,653+33.0% | Added |
| Marshall Wace, LLP | 1,284,950 | $15.4M | 0.01% | +1,284,950 | New |
Holders of 5% or more of RGNX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of REGENXBIO Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Redmile Group, LLC | 13G/A | 9.90%5.06M shares | – | Feb 16, 20216 filings | Aug 14, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 7.30%3.68M shares | −3.70 ppfrom 11.00% | Jan 8, 20252 filings | Apr 24, 2025 | SEC |
| JPMorgan Chase & Co | 13G | 5.30%3.56M shares | +0.90 ppfrom 4.40% | Jan 15, 202110 filings | Oct 13, 2026 | SEC |